Christina Kay
2024
In 2024, Christina Kay earned a total compensation of $343.6K as Co, Chief Executive Officer at Integrated Biopharma, a 14% increase compared to previous year.
Compensation breakdown
| Bonus | $5,300 |
|---|---|
| Option Awards | $60,060 |
| Salary | $268,000 |
| Other | $10,193 |
| Total | $343,553 |
Kay received $268K in salary, accounting for 78% of the total pay in 2024.
Kay also received $5.3K in bonus, $60.1K in option awards and $10.2K in other compensation.
Rankings
In 2024, Christina Kay's compensation ranked 157th out of 207 executives tracked by ExecPay. In other words, Kay earned more than 24.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 157 out of 207 | 24th |
Division Manufacturing | 63 out of 89 | 29th |
Major group Chemicals And Allied Products | 27 out of 36 | 25th |
Industry group Drugs | 27 out of 33 | 18th |
Industry Pharmaceutical Preparations | 25 out of 30 | 17th |
Source: SEC filing on October 28, 2024.
Kay's colleagues
We found two more compensation records of executives working with Christina Kay at Integrated Biopharma in 2024.
News
Integrated Biopharma CFO Dina Masi's 2024 pay rises 8% to $357K
October 28, 2024
Integrated Biopharma CFO Dina Masi's 2023 pay rises 10% to $330K
October 27, 2023
Integrated Biopharma CFO Dina Masi's 2022 pay rises 12% to $300K
October 27, 2022
Integrated Biopharma CFO Dina Masi's 2021 pay rises 6% to $268K
October 27, 2021
Integrated Biopharma CFO Dina Masi's 2019 pay rises 4% to $251K
October 28, 2019